- $3.93m
- $3.94m
- $0.02m
NASDAQ RESUMED AT 12:50 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:45 PM
NASDAQ RESUMED AT 12:45 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:20 PM
NASDAQ RESUMED AT 10:12 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:02 AM
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002
Brief: Jupiter Neurosciences - Files For Resale Of Up To 16 Million Shares By Selling Stockholder - SEC Filing
Brief: Jupiter Neurosciences Says Patient Enrollment Underway In Phase 2A Reset Trial In Parkinson's Disease
Brief: Jupiter Neurosciences Expands Nugevia Addressable Market with Focus on GLP-1 Users
Brief: Jupiter Neurosciences Files Rospectus Related To Resale Of Up To 10 Million Shares Of Our Common Stock By Selling Stockholder
Brief: Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL in Parkinson’s Disease
Brief: Jupiter Neurosciences Enters Into Agreements For Up To $20 Million In Flexible Financing
Brief: Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product Development
Brief: Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products
Brief: Jupiter Neurosciences, Inc. Announces Closing Of $11 Million Initial Public Offering